Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q86XP0
UPID:
PA24D_HUMAN
Alternative names:
Phospholipase A2 group IVD
Alternative UPACC:
Q86XP0; Q8N176
Background:
Cytosolic phospholipase A2 delta, also known as Phospholipase A2 group IVD, plays a crucial role in cellular processes by selectively hydrolyzing glycerophospholipids at the sn-2 position. It exhibits a preference for linoleic acid, highlighting its specificity in lipid metabolism.
Therapeutic significance:
Understanding the role of Cytosolic phospholipase A2 delta could open doors to potential therapeutic strategies. Its precise function in lipid metabolism makes it an intriguing target for addressing disorders related to lipid dysregulation.